1. Monoclonal Antibody Therapy in a Vaccine Breakthrough SARS-CoV-2 Hospitalized Delta (B.1.617.2) Variant Case
- Author
-
Marina Rogova, Niamh B. O’Hara, Bradley A. Connor, Morgan Gardner, Joseph E. Barrows, Mara Couto-Rodriguez, and Dorottya Nagy-Szakal
- Subjects
Microbiology (medical) ,Delta ,Delta variant ,2019-20 coronavirus outbreak ,Coronavirus disease 2019 (COVID-19) ,medicine.drug_class ,Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) ,Case Report ,bamlanivimab/etesevimab ,Infectious and parasitic diseases ,RC109-216 ,Monoclonal antibody ,medicine ,breakthrough ,Monoclonal antibody therapy ,B.1.617.2 ,SARS-CoV-2 ,business.industry ,monoclonal antibody therapy ,COVID-19 ,General Medicine ,Virology ,Titer ,Infectious Diseases ,business ,variant of concern - Abstract
We present two Delta (B.1.617.2) vaccine breakthrough individuals, a father and son living in separate households. The older, 63-year-old patient's symptoms were severe enough to require hospitalization. Despite having a high titer of anti-spike IgG in his serum, his symptoms resolved within 24 hours following monoclonal antibody (bamlanivimab/etesevimab) therapy.
- Published
- 2021
- Full Text
- View/download PDF